{
    "pmcid": "7844813",
    "qa_pairs": {
        "What advantage do nanobodies have over conventional antibodies according to the study?": [
            "Better tissue penetration and lower immunogenicity",
            "Higher molecular weight and longer half-life",
            "Broader specificity and increased cross-reactivity",
            "Greater resistance to proteolytic degradation"
        ],
        "What expression system was used for producing the nanobodies in the study?": [
            "HEK293FT cells",
            "CHO cells",
            "E. coli",
            "Yeast"
        ],
        "What is the primary target of the nanobodies developed in the study for blocking SARS-CoV-2 infection?": [
            "The receptor-binding domain (RBD) of the spike protein",
            "The S2 subunit of the spike protein",
            "The nucleocapsid protein",
            "The membrane protein"
        ],
        "What method was used to purify the nanobodies expressed in the study?": [
            "Ni-NTA affinity chromatography",
            "Size-exclusion chromatography",
            "Ion-exchange chromatography",
            "Hydrophobic interaction chromatography"
        ],
        "Which nanobody construct exhibited the strongest RBD-binding affinity and neutralizing ability against SARS-CoV-2 pseudoviruses?": [
            "The heterodimer Nb91-Nb3-hFc",
            "The homodimer Nb91-hFc",
            "The homotrimer Nb3-hFc",
            "The monomer Nb91"
        ]
    }
}